- Home
- SRAD vs ARWR Comparison
SRAD vs ARWR Comparison
Compare SRAD & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | ARWR |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 10.1B |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SRAD | ARWR |
|---|---|---|
| Price | $18.34 | $59.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | $30.18 | ★ $81.50 |
| AVG Volume (30 Days) | ★ 2.2M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $24.65 | N/A |
| Revenue Next Year | $15.05 | N/A |
| P/E Ratio | ★ $49.48 | $270.84 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.73 | $10.66 |
| 52 Week High | $32.22 | $76.76 |
Technical Indicators
Market Signals| Indicator | SRAD | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 39.51 |
| Support Level | $16.21 | $36.34 |
| Resistance Level | $19.67 | $66.37 |
| Average True Range (ATR) | 0.87 | 2.92 |
| MACD | 0.20 | -0.33 |
| Stochastic Oscillator | 53.87 | 25.56 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.